2ndB

SecondBrain (2ndB) is redefining preclinical drug testing for Parkinson’s disease, the fastest-growing neurological disorder worldwide. Despite decades of research, no therapy has succeeded in halting disease progression — largely due to the poor predictive power of traditional animal models. 2ndB’s Tunnel-MEA platform offers a breakthrough alternative, combining human brain organoids with advanced microelectrode technology to capture clear, high-resolution signals of neural activity that existing systems cannot achieve.

The Tunnel-MEA records signals from single axons with an exceptionally high signal-to-noise ratio, enabling real-time, human-relevant insights into brain function. Complementing the hardware, 2ndB’s AI-powered software translates complex electrophysiological data into functional biomarkers, giving pharmaceutical companies a reliable way to evaluate drug efficacy before clinical trials.

Validated with both healthy and Parkinson’s disease organoids, this integrated system has already shown over 70% accuracy in distinguishing diseased from healthy tissues. Led by experts in chip technology, AI, and life sciences entrepreneurship, SecondBrain bridges the gap between preclinical models and clinical outcomes—helping accelerate the development of effective neurotherapies.

(Previous information: Venture Challenge Fall 2020, Thom Frielink, Andrea Soto Padilla, Regina Luttge, Yağmur Demircan Yalçın)